An 8-week, prospective, randomized, investigator-blinded, parallel-group, multinational study compared the effects on quality of life (QoL) of a calcipotriol and betamethasone formulation (CB) with calcipotriol (C) solution alone in 312 patients with moderately severe scalp psoriasis. CB and C were applied once daily and QoL was assessed at baseline, weeks 0, 2, 4 and 8 weeks with the Short Form-36 version 2 (SF-36v2) and Skindex-16 scales. CB was significantly superior to C on the Physical and Mental Component Summary Items of the SF-36v2 scale at 8 weeks (P < 0.005 and P < 0.05, respectively). Calcipotriol alone produced a significant decrease from baseline only on the Mental Component summary of the ...